Advertisement

Clinical Journal of Gastroenterology

, Volume 12, Issue 6, pp 534–538 | Cite as

Neuroendocrine carcinoma of the esophagus with an adenocarcinoma component

  • Yuki Kaneko
  • Shin SaitoEmail author
  • Kazuya Takahashi
  • Rihito Kanamaru
  • Yoshinori Hosoya
  • Hironori Yamaguchi
  • Joji Kitayama
  • Toshiro Niki
  • Alan Kawarai Lefor
  • Naohiro Sata
Case Report
  • 90 Downloads

Abstract

A 68-year-old male was referred with dysphagia. Endoscopic findings showed circular stenosis with a protruding mass in the lower esophagus. Biopsy showed adenocarcinoma and there was no evidence of distant metastases. A subtotal esophagectomy was performed. The resected specimen revealed a mixed neuroendocrine carcinoma with adenocarcinoma. The adenocarcinoma component was on the surface of the tumor and the neuroendocrine component invaded the deeper portion. Immunohistochemically, the neuroendocrine carcinoma component stained positive for cytokeratin 7 and cytokeratin 20, suggesting that the neuroendocrine carcinoma originated from the adenocarcinoma. The adenocarcinoma component stained positive for MUC2, which suggests that the adenocarcinoma component originated from Barrett’s epithelium. Taken together, the neuroendocrine carcinoma may have originated from Barrett’s epithelium. A metastasis to the liver was found 2 months after the surgical resection. Chemotherapy was administered, but there was no response. Most esophageal neuroendocrine carcinomas are accompanied by adenocarcinoma or squamous cell components, suggesting that these carcinomas originate from pluripotent cells in squamous or Barrett’s epithelium. Appropriate chemotherapy for these lesions should be considered based on the cell of origin.

Keywords

Esophageal neuroendocrine carcinoma Mixed adenoneuroendocrine carcinoma Barrett’s esophagus Origin of neuroendocrine carcinomas 

Abbreviations

SCC

Squamous cell carcinoma

CT

Computed tomography

Notes

Acknowledgements

The authors declare no conflicts of interests and no funds regarding the publication of this paper.

Compliance with ethical standards

Conflict of interest

Yuki Kaneko, Shin Saito, Kazuya Takahashi, Rihito Kanamaru, Shiro Matsumoto, Yoshinori Hosoya, Hirofumi Fujii, Joji Kitayama, Toshiro Niki, Alan Kawarai Lefor and Naohiro Sata declare that they have no conflict of interest.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Ethical approval

The need for ethical approval for this paper was waived by the committee of Jichi Medical University Hospital.

References

  1. 1.
    Kitajima T, Kaida S, Lee S, et al. Mixed adeno (neuro) endocrine carcinoma arising from the ectopic gastric mucosa of the upper thoracic esophagus. World J Surg Oncol. 2013;11:218.CrossRefGoogle Scholar
  2. 2.
    Egashira A, Morita M, Kumagai R, et al. Neuroendocrine carcinoma of the esophagus: clinicopathological and immunohistochemical features of 14 cases. PLoS One. 2017;12:e0173501.CrossRefGoogle Scholar
  3. 3.
    Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. 4th ed. International Agency for Research on Cancer. Lyon: IARC Press; 2010.Google Scholar
  4. 4.
    Deng HY, Ni PZ, Wang YC, et al. Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis. 2016;8:1250–6.CrossRefGoogle Scholar
  5. 5.
    Kadhim MM, Jespersen ML, Pilegaard HK, et al. Mixed adenoneuroendocrine carcinoma is a rare but important tumour found in the oesophagus. Case Rep Gastrointest Med. 2016;2016:9542687.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Tustumi F, Takeda FR, Uema RH, et al. Primary neuroendocrine neoplasm of the esophagus—report of 14 cases from a single institute and review of the literature. Arq Gastroenterol. 2017;54:4–10.CrossRefGoogle Scholar
  7. 7.
    Xiao X, Wang S, Xia S, et al. Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung tumor. OncoTargets Therapy. 2015;8:2209–14.CrossRefGoogle Scholar
  8. 8.
    Asayama M, Fuse N, Yoshino T, et al. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases. Cancer Chemother Pharmacol. 2011;68:1325–30.CrossRefGoogle Scholar
  9. 9.
    Maru DM, Khurana H, Rashid A, et al. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008;32:1404–11.CrossRefGoogle Scholar
  10. 10.
    Cary NR, Barron DJ, McGoldrick JP, et al. Combined oesophageal adenocarcinoma and carcinoid in Barrett’s oesophagitis: potential role of enterochromaffin-like cells in oesophageal malignancy. Thorax. 1993;48:404–5.CrossRefGoogle Scholar
  11. 11.
    McIntire MG, Soucy G, Vaughan TL, et al. MUC2 is a highly specific marker of goblet cell metaplasia in the distal esophagus and gastroesophageal junction. Am J Surg Pathol. 2011;35:1007–13.CrossRefGoogle Scholar
  12. 12.
    Turkmen IC, Bassullu N, Uraz S, et al. CDX2, COX2 and MUC2 expressions in Barrett’s esophagus: can they be useful in determination of the dysplasia? Turk patoloji dergisi. 2012;28:251–8.PubMedGoogle Scholar
  13. 13.
    Saint Martin MC, Chejfec G. Barrett esophagus-associated small cell carcinoma. Arch Pathol Lab Med. 1999;123:1123.PubMedGoogle Scholar
  14. 14.
    Okuma HS, Iwasa S, Shoji H, et al. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus. Anticancer Res. 2014;34:5037–41.PubMedGoogle Scholar
  15. 15.
    Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRefGoogle Scholar
  16. 16.
    Saif MW, Vethody C. Poorly differentiated neuroendocrine tumor of the esophagus with hypertrophic osteoarthropathy and brain metastasis: a success story. Cureus. 2016;8:646.Google Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  • Yuki Kaneko
    • 1
  • Shin Saito
    • 1
    Email author
  • Kazuya Takahashi
    • 1
  • Rihito Kanamaru
    • 1
  • Yoshinori Hosoya
    • 1
  • Hironori Yamaguchi
    • 3
  • Joji Kitayama
    • 1
  • Toshiro Niki
    • 2
  • Alan Kawarai Lefor
    • 1
  • Naohiro Sata
    • 1
  1. 1.Department of SurgeryJichi Medical UniversityShimotsukeJapan
  2. 2.Department of PathologyJichi Medical UniversityShimotsukeJapan
  3. 3.Department of Clinical OncologyJichi Medical UniversityShimotsukeJapan

Personalised recommendations